CETP

Cholesteryl ester transfer protein · P11597 · CETP on Sugi Atlas →

103,210 patent compounds predicted against CETP, 57,406 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Torcetrapib (SCHEMBL49081)	1.00	20/20
Evacetrapib (SCHEMBL108367)	1.00	20/20
Evacetrapib (SCHEMBL108602)	1.00	20/20
Torcetrapib (SCHEMBL126708)	1.00	20/20
Evacetrapib (SCHEMBL141340)	1.00	20/20
Evacetrapib (SCHEMBL139419)	0.99	20/20
Evacetrapib (SCHEMBL139421)	0.99	20/20
Evacetrapib (SCHEMBL141256)	0.99	20/20
Evacetrapib (SCHEMBL141258)	0.99	20/20
Evacetrapib (SCHEMBL141317)	0.99	20/20
Evacetrapib (SCHEMBL141318)	0.99	20/20
Evacetrapib (SCHEMBL145129)	0.99	20/20
Evacetrapib (SCHEMBL145131)	0.99	20/20
Evacetrapib (SCHEMBL142799)	0.97	20/20
SCHEMBL109517	0.96	20/20
Evacetrapib (SCHEMBL142980)	0.96	20/20
Evacetrapib (SCHEMBL142982)	0.96	20/20
Evacetrapib (SCHEMBL139142)	0.95	20/20
Evacetrapib (SCHEMBL141664)	0.95	20/20
Evacetrapib (SCHEMBL141665)	0.95	20/20

Clinical trials — most relevant to CETP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Low HDL On Six Weeks Statin Therapy (LOW) Study	PHASE4	UNKNOWN
Effect of Rosuvastatin Therapy on HDL2 Level	PHASE4	UNKNOWN
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients	PHASE4	COMPLETED
The HDL Particle Protection Study	PHASE4	COMPLETED
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons	PHASE4	COMPLETED
Effect of Evolocumab on Vascular Function	PHASE4	COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes	PHASE3	COMPLETED
Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)	PHASE3	COMPLETED
A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels	PHASE2	COMPLETED
TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)	PHASE2	COMPLETED
To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors	PHASE2	COMPLETED
Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease	nan	UNKNOWN
Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)	nan	COMPLETED
Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors	nan	COMPLETED
Genetic and Metabolism of Post-prandial HDL Particles	nan	COMPLETED
The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk	nan	COMPLETED
Identification of CETP as a Marker of Atherosclerosis	nan	COMPLETED
Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals	nan	COMPLETED
Nutrigenetic Intervention on Blood Lipid Markers and Body Composition of Adults With Overweight and Obesity	nan	COMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects	nan	UNKNOWN
Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease	nan	UNKNOWN
Trans Fatty Acids and Cardiovascular Risk Factors	nan	COMPLETED
Assessment of Epicardial Fat Thickness in Children With Familial Dyslipidemia	nan	UNKNOWN
HIV Reverse Cholesterol Transport Study	nan	UNKNOWN
Omega-3 on Lipid Profile and Serum Leptin Level n Neonates With Intrauterine Growth Restriction	nan	COMPLETED
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN
Advanced Lipoproptein Profiling and Cardiovascular Risk Stratification in Familial Hypercholesterolemia	nan	UNKNOWN
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux	nan	COMPLETED
Study the Role of Genetic Variation in the Determining Lipid Profile Response to Dietary Change	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CETP binder may also engage these)

Protein	Name	Similarity
P47896	—	1.000	P47896 →
Q3V6R6	—	1.000	Q3V6R6 →
G3HIK4	—	1.000	G3HIK4 →
P22687	—	0.999	P22687 →
Q61114	—	0.998	Q61114 →
Q8TDL5	—	0.997	Q8TDL5 →
P55065	—	0.997	P55065 →
A0JPN3	—	0.993	A0JPN3 →
Q8C186	—	0.992	Q8C186 →
PLTP	Phospholipid transfer protein	0.992	landscape →
Q8BU51	—	0.991	Q8BU51 →
Q8SPF8	—	0.988	Q8SPF8 →
Q05701	—	0.987	Q05701 →
Q8N4F0	—	0.986	Q8N4F0 →
P25914	—	0.986	P25914 →
Q8C1E1	—	0.984	Q8C1E1 →
Q63313	—	0.983	Q63313 →
Q8NFQ6	—	0.982	Q8NFQ6 →
Q61805	—	0.980	Q61805 →
Q2TBI0	—	0.980	Q2TBI0 →
Q8NFQ5	—	0.979	Q8NFQ5 →
Q86YQ2	—	0.979	Q86YQ2 →
Q67E05	—	0.979	Q67E05 →
P59827	—	0.979	P59827 →
Q6AXU0	—	0.978	Q6AXU0 →
Q96DR5	—	0.978	Q96DR5 →
Q80ZU7	—	0.978	Q80ZU7 →
Q93796	—	0.977	Q93796 →
P17454	—	0.977	P17454 →
Q8VYC2	—	0.977	Q8VYC2 →